Abingworth
Overview
Abingworth is a transatlantic life sciences investment firm that helps transform cutting-edge science into novel medicines by providing capital and expertise to management teams building world-class companies.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Tizona Therapeutics | Mar 2016 | Series B | Lead |
| Atsena Therapeutics | Apr 2025 | Series C | Co-investor |
| Pathalys Pharma | Jan 2023 | Early Funding | Lead |
| Xiasma Limited | Feb 2015 | Series E | Co-investor |
| Timberlyne Therapeutics | Jan 2025 | Series A | Lead |
For institutional investors. Book with your work email.
Key People
Kurt von Emster
Managing Partner, Head of Life Sciences
Tim Haines
Managing Director And Executive Partner
Ibraheem Mahmood
Operating Partner
Carlos Paya
Venture Partner
Natalie Mount
Venture Partner
Andrew Sinclair
Partner, Portfolio Manager
GLH Lloyd-Harris
Partner
Bali Muralidhar
Managing Partner, Chief Investment Officer, Managing Partner
Diya Malhotra
Principal
Graham Mills
Principal
Jay Cui
Principal
Lucille Conroy
Principal
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Abingworth based?
Abingworth is headquartered in London, United Kingdom.
When was Abingworth founded?
Abingworth was founded in 1973.
How many portfolio companies does Abingworth have?
Abingworth has 35 portfolio companies in Caplight's dataset.
What are some companies in Abingworth's portfolio?
Portfolio companies visible on Caplight include Tizona Therapeutics, Atsena Therapeutics, Pathalys Pharma, Xiasma Limited, Timberlyne Therapeutics.
What was Abingworth's most recent investment shown here?
Abingworth's most recent investment in this portfolio sample was in Atsena Therapeutics in 2025.
What sectors does Abingworth focus on?
Abingworth focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software, AI, Data & Cloud Infrastructure.
What company stages does Abingworth focus on?
Abingworth typically invests at the MultiStage stage.
What is Abingworth's AUM?
Abingworth's assets under management are estimated between $1.0B and $10.0B.